Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing
Mandate

Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing

February 15, 2016

Vinge advises BioGaia AB (publ) and its subsidiary Infant Bacterial Therapeutics AB (publ) ("IBT") in connection with the proposed distribution of BioGaia’s shares in IBT to the shareholders of BioGaia. In connection with the distribution, IBT will apply for listing of the company's series B shares on Nasdaq First North. IBT is developing a drug (IBP-9414) against necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Vinge's team consists of Erik Sjöman, Dain Hård Nevonen, Ludvig Frithiof and Joel Wahlberg. Tora Hansjons advises on tax matters.

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

 Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

 Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026